Greenwich LifeSciences Stock (NASDAQ:GLSI)
Previous Close
$13.01
52W Range
$8.00 - $21.44
50D Avg
$13.62
200D Avg
$14.68
Market Cap
$161.42M
Avg Vol (3M)
$28.45K
Beta
3.32
Div Yield
-
GLSI Company Profile
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
GLSI Performance
Peer Comparison
Ticker | Company |
---|---|
RVPH | Reviva Pharmaceuticals Holdings, Inc. |
DAWN | Day One Biopharmaceuticals, Inc. |
PDSB | PDS Biotechnology Corporation |
ACXP | Acurx Pharmaceuticals, Inc. |
INZY | Inozyme Pharma, Inc. |
XFOR | X4 Pharmaceuticals, Inc. |
AVXL | Anavex Life Sciences Corp. |
NXTC | NextCure, Inc. |
VRPX | Virpax Pharmaceuticals, Inc. |
IMMP | Immutep Limited |
MNOV | MediciNova, Inc. |
ABOS | Acumen Pharmaceuticals, Inc. |
ENTX | Entera Bio Ltd. |
TERN | Terns Pharmaceuticals, Inc. |
EYEN | Eyenovia, Inc. |
AMLX | Amylyx Pharmaceuticals, Inc. |